Do aluminium-based phosphate binders continue to have a role in contemporary nephrology practice?
Aluminium-containing phosphate binders have long been used for treatment of hyperphosphatemia in dialysis patients. Their safety became controversial in the early 1980's after reports of aluminium related neurological and bone disease began to appear. Available historical evidence however, sugg...
Saved in:
Published in | BMC nephrology Vol. 12; no. 1; p. 20 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central Ltd
13.05.2011
BioMed Central BMC |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Aluminium-containing phosphate binders have long been used for treatment of hyperphosphatemia in dialysis patients. Their safety became controversial in the early 1980's after reports of aluminium related neurological and bone disease began to appear. Available historical evidence however, suggests that neurological toxicity may have primarily been caused by excessive exposure to aluminium in dialysis fluid, rather than aluminium-containing oral phosphate binders. Limited evidence suggests that aluminium bone disease may also be on the decline in the era of aluminium removal from dialysis fluid, even with continued use of aluminium binders.
The K/DOQI and KDIGO guidelines both suggest avoiding aluminium-containing binders. These guidelines will tend to promote the use of the newer, more expensive binders (lanthanum, sevelamer), which have limited evidence for benefit and, like aluminium, limited long-term safety data. Treating hyperphosphatemia in dialysis patients continues to represent a major challenge, and there is a large body of evidence linking serum phosphate concentrations with mortality. Most nephrologists agree that phosphate binders have the potential to meaningfully reduce mortality in dialysis patients. Aluminium is one of the cheapest, most effective and well tolerated of the class, however there are no prospective or randomised trials examining the efficacy and safety of aluminium as a binder. Aluminium continues to be used as a binder in Australia as well as some other countries, despite concern about the potential for toxicity. There are some data from selected case series that aluminium bone disease may be declining in the era of reduced aluminium content in dialysis fluid, due to rigorous water testing.
This paper seeks to revisit the contemporary evidence for the safety record of aluminium-containing binders in dialysis patients. It puts their use into the context of the newer, more expensive binders and increasing concerns about the risks of calcium binders, which continue to be widely used. The paper seeks to answer whether the continued use of aluminium is justifiable in the absence of prospective data establishing its safety, and we call for prospective trials to be conducted comparing the available binders both in terms of efficacy and safety. |
---|---|
AbstractList | Abstract Background Aluminium-containing phosphate binders have long been used for treatment of hyperphosphatemia in dialysis patients. Their safety became controversial in the early 1980's after reports of aluminium related neurological and bone disease began to appear. Available historical evidence however, suggests that neurological toxicity may have primarily been caused by excessive exposure to aluminium in dialysis fluid, rather than aluminium-containing oral phosphate binders. Limited evidence suggests that aluminium bone disease may also be on the decline in the era of aluminium removal from dialysis fluid, even with continued use of aluminium binders. Discussion The K/DOQI and KDIGO guidelines both suggest avoiding aluminium-containing binders. These guidelines will tend to promote the use of the newer, more expensive binders (lanthanum, sevelamer), which have limited evidence for benefit and, like aluminium, limited long-term safety data. Treating hyperphosphatemia in dialysis patients continues to represent a major challenge, and there is a large body of evidence linking serum phosphate concentrations with mortality. Most nephrologists agree that phosphate binders have the potential to meaningfully reduce mortality in dialysis patients. Aluminium is one of the cheapest, most effective and well tolerated of the class, however there are no prospective or randomised trials examining the efficacy and safety of aluminium as a binder. Aluminium continues to be used as a binder in Australia as well as some other countries, despite concern about the potential for toxicity. There are some data from selected case series that aluminium bone disease may be declining in the era of reduced aluminium content in dialysis fluid, due to rigorous water testing. Summary This paper seeks to revisit the contemporary evidence for the safety record of aluminium-containing binders in dialysis patients. It puts their use into the context of the newer, more expensive binders and increasing concerns about the risks of calcium binders, which continue to be widely used. The paper seeks to answer whether the continued use of aluminium is justifiable in the absence of prospective data establishing its safety, and we call for prospective trials to be conducted comparing the available binders both in terms of efficacy and safety. BACKGROUND: Aluminium-containing phosphate binders have long been used for treatment of hyperphosphatemia in dialysis patients. Their safety became controversial in the early 1980's after reports of aluminium related neurological and bone disease began to appear. Available historical evidence however, suggests that neurological toxicity may have primarily been caused by excessive exposure to aluminium in dialysis fluid, rather than aluminium-containing oral phosphate binders. Limited evidence suggests that aluminium bone disease may also be on the decline in the era of aluminium removal from dialysis fluid, even with continued use of aluminium binders. DISCUSSION: The K/DOQI and KDIGO guidelines both suggest avoiding aluminium-containing binders. These guidelines will tend to promote the use of the newer, more expensive binders (lanthanum, sevelamer), which have limited evidence for benefit and, like aluminium, limited long-term safety data. Treating hyperphosphatemia in dialysis patients continues to represent a major challenge, and there is a large body of evidence linking serum phosphate concentrations with mortality. Most nephrologists agree that phosphate binders have the potential to meaningfully reduce mortality in dialysis patients. Aluminium is one of the cheapest, most effective and well tolerated of the class, however there are no prospective or randomised trials examining the efficacy and safety of aluminium as a binder. Aluminium continues to be used as a binder in Australia as well as some other countries, despite concern about the potential for toxicity. There are some data from selected case series that aluminium bone disease may be declining in the era of reduced aluminium content in dialysis fluid, due to rigorous water testing. SUMMARY: This paper seeks to revisit the contemporary evidence for the safety record of aluminium-containing binders in dialysis patients. It puts their use into the context of the newer, more expensive binders and increasing concerns about the risks of calcium binders, which continue to be widely used. The paper seeks to answer whether the continued use of aluminium is justifiable in the absence of prospective data establishing its safety, and we call for prospective trials to be conducted comparing the available binders both in terms of efficacy and safety. Aluminium-containing phosphate binders have long been used for treatment of hyperphosphatemia in dialysis patients. Their safety became controversial in the early 1980's after reports of aluminium related neurological and bone disease began to appear. Available historical evidence however, suggests that neurological toxicity may have primarily been caused by excessive exposure to aluminium in dialysis fluid, rather than aluminium-containing oral phosphate binders. Limited evidence suggests that aluminium bone disease may also be on the decline in the era of aluminium removal from dialysis fluid, even with continued use of aluminium binders. The K/DOQI and KDIGO guidelines both suggest avoiding aluminium-containing binders. These guidelines will tend to promote the use of the newer, more expensive binders (lanthanum, sevelamer), which have limited evidence for benefit and, like aluminium, limited long-term safety data. Treating hyperphosphatemia in dialysis patients continues to represent a major challenge, and there is a large body of evidence linking serum phosphate concentrations with mortality. Most nephrologists agree that phosphate binders have the potential to meaningfully reduce mortality in dialysis patients. Aluminium is one of the cheapest, most effective and well tolerated of the class, however there are no prospective or randomised trials examining the efficacy and safety of aluminium as a binder. Aluminium continues to be used as a binder in Australia as well as some other countries, despite concern about the potential for toxicity. There are some data from selected case series that aluminium bone disease may be declining in the era of reduced aluminium content in dialysis fluid, due to rigorous water testing. This paper seeks to revisit the contemporary evidence for the safety record of aluminium-containing binders in dialysis patients. It puts their use into the context of the newer, more expensive binders and increasing concerns about the risks of calcium binders, which continue to be widely used. The paper seeks to answer whether the continued use of aluminium is justifiable in the absence of prospective data establishing its safety, and we call for prospective trials to be conducted comparing the available binders both in terms of efficacy and safety. Aluminium-containing phosphate binders have long been used for treatment of hyperphosphatemia in dialysis patients. Their safety became controversial in the early 1980's after reports of aluminium related neurological and bone disease began to appear. Available historical evidence however, suggests that neurological toxicity may have primarily been caused by excessive exposure to aluminium in dialysis fluid, rather than aluminium-containing oral phosphate binders. Limited evidence suggests that aluminium bone disease may also be on the decline in the era of aluminium removal from dialysis fluid, even with continued use of aluminium binders. The K/DOQI and KDIGO guidelines both suggest avoiding aluminium-containing binders. These guidelines will tend to promote the use of the newer, more expensive binders (lanthanum, sevelamer), which have limited evidence for benefit and, like aluminium, limited long-term safety data. Treating hyperphosphatemia in dialysis patients continues to represent a major challenge, and there is a large body of evidence linking serum phosphate concentrations with mortality. Most nephrologists agree that phosphate binders have the potential to meaningfully reduce mortality in dialysis patients. Aluminium is one of the cheapest, most effective and well tolerated of the class, however there are no prospective or randomised trials examining the efficacy and safety of aluminium as a binder. Aluminium continues to be used as a binder in Australia as well as some other countries, despite concern about the potential for toxicity. There are some data from selected case series that aluminium bone disease may be declining in the era of reduced aluminium content in dialysis fluid, due to rigorous water testing. This paper seeks to revisit the contemporary evidence for the safety record of aluminium-containing binders in dialysis patients. It puts their use into the context of the newer, more expensive binders and increasing concerns about the risks of calcium binders, which continue to be widely used. The paper seeks to answer whether the continued use of aluminium is justifiable in the absence of prospective data establishing its safety, and we call for prospective trials to be conducted comparing the available binders both in terms of efficacy and safety. |
ArticleNumber | 20 |
Audience | Academic |
Author | Isbel, Nicole M van Eps, Carolyn L Hawley, Carmel M Petrie, James J B Mudge, David W Campbell, Scott B Johnson, David W |
AuthorAffiliation | 1 Department of Nephrology, University of Queensland at Princess Alexandra Hospital, Ipswich Road, Woolloongabba, Queensland, Australia |
AuthorAffiliation_xml | – name: 1 Department of Nephrology, University of Queensland at Princess Alexandra Hospital, Ipswich Road, Woolloongabba, Queensland, Australia |
Author_xml | – sequence: 1 givenname: David W surname: Mudge fullname: Mudge, David W email: david_mudge@health.qld.gov.au organization: Department of Nephrology, University of Queensland at Princess Alexandra Hospital, Ipswich Road, Woolloongabba, Queensland, Australia. david_mudge@health.qld.gov.au – sequence: 2 givenname: David W surname: Johnson fullname: Johnson, David W – sequence: 3 givenname: Carmel M surname: Hawley fullname: Hawley, Carmel M – sequence: 4 givenname: Scott B surname: Campbell fullname: Campbell, Scott B – sequence: 5 givenname: Nicole M surname: Isbel fullname: Isbel, Nicole M – sequence: 6 givenname: Carolyn L surname: van Eps fullname: van Eps, Carolyn L – sequence: 7 givenname: James J B surname: Petrie fullname: Petrie, James J B |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/21569446$$D View this record in MEDLINE/PubMed |
BookMark | eNp1ks1r3DAQxU1JaT7ac29F0LMTfdu-tCRp2gYCvbRnMZLHawVbMrI3kP--2jhdspCig8S8px9PmjktjkIMWBQfGT1nrNYXTFas5EI3JeMlp2-Kk33l6MX5uDid53tKWVVL-q445kzpRkp9UsC3SGDYjj747VhamLElUx_nqYcFifWhxTQTF8PiwxbJEkkPD0iApDgg8eFJwnGKCdIjCTj1WYibRzIlcIt3-PV98baDYcYPz_tZ8ef7ze_rn-Xdrx-315d3pVW1XEoNQkoA4FK3FW85rZ12rlbMNo0THVeqq9BR2TpqbUOxwUpLwMpxAUoLKs6K25XbRrg3U_JjTmQiePNUiGljIOVEA5paadVJ2wmKTGJLoVYIwlKlrGqdhMz6srKmrR2xdRiWBMMB9FAJvjeb-GAEoxXTTQZcrQDr438Ah4qLo9m1y-zaZRg3fPeizytkAzm0D13MVjf62ZlLrmpKpWA6u85fceXV4uhzd7DzuX5w4WK94FKc54TdPhajZjdVrwT59PI79v5_YyT-An_Myw0 |
CitedBy_id | crossref_primary_10_1080_0886022X_2022_2104165 crossref_primary_10_1039_c2dt31601c crossref_primary_10_1155_2017_9035193 crossref_primary_10_1016_j_fct_2011_10_072 crossref_primary_10_1111_hdi_12231 crossref_primary_10_4162_nrp_2013_7_6_466 crossref_primary_10_1080_14656566_2018_1491548 crossref_primary_10_1517_14656566_2011_626768 crossref_primary_10_1111_hdi_12173 crossref_primary_10_1136_bcr_2020_239322 crossref_primary_10_3109_10408444_2014_934439 crossref_primary_10_1080_03601234_2020_1794220 crossref_primary_10_1517_14740338_2014_907791 crossref_primary_10_1016_j_ekir_2019_06_002 crossref_primary_10_32947_ajps_v20i3_764 crossref_primary_10_1111_sdi_12418 crossref_primary_10_1007_s40620_016_0266_9 crossref_primary_10_1517_14656566_2013_852183 crossref_primary_10_1007_s40265_016_0575_2 crossref_primary_10_5372_1905_7415_0804_317 crossref_primary_10_11622_smedj_2013105 crossref_primary_10_1186_1471_2369_12_55 crossref_primary_10_1186_s12882_022_02688_9 crossref_primary_10_1016_j_colsurfa_2021_126813 crossref_primary_10_1007_s11560_017_0149_7 crossref_primary_10_33320_maced_pharm_bull_2017_63_01_001 crossref_primary_10_2146_ajhp160559 crossref_primary_10_4155_cli_14_110 crossref_primary_10_1007_s40267_017_0441_7 crossref_primary_10_1016_j_etap_2020_103404 crossref_primary_10_1517_14656566_2014_928285 crossref_primary_10_1007_s00210_020_02012_y crossref_primary_10_1016_j_clay_2019_105259 crossref_primary_10_1097_MNH_0000000000000418 |
Cites_doi | 10.1038/ki.1981.56 10.1111/j.1440-1797.2006.00712.x 10.2215/CJN.04211007 10.1056/NEJM197601222940402 10.1038/ki.1987.177 10.1097/00000441-198901000-00003 10.1016/S0140-6736(76)92177-2 10.1001/archneur.1981.00510100084016 10.1053/j.ajkd.2005.04.020 10.1093/ndt/12.12.2679 10.1056/NEJM198404263101704 10.1097/01.ASN.0000133041.27682.A2 10.1016/S0140-6736(79)90883-3 10.1177/089686080602600308 10.1172/JCI106517 10.1038/sj.ki.5002466 10.1093/ndt/gfl146 10.1111/j.1523-1755.2005.00171.x 10.1258/0004563053026862 10.1111/j.1440-1754.1992.tb02658.x 10.1097/00002480-197301900-00077 10.1016/S0272-6386(03)00905-3 10.1111/j.1523-1755.2004.00877.x 10.1016/0022-510X(92)90291-R 10.1038/ki.1989.286 10.1016/S0272-6386(99)70394-X |
ContentType | Journal Article |
Copyright | 2011 Mudge et al; licensee BioMed Central Ltd. COPYRIGHT 2011 BioMed Central Ltd. Copyright ©2011 Mudge et al; licensee BioMed Central Ltd. 2011 Mudge et al; licensee BioMed Central Ltd. |
Copyright_xml | – notice: 2011 Mudge et al; licensee BioMed Central Ltd. – notice: COPYRIGHT 2011 BioMed Central Ltd. – notice: Copyright ©2011 Mudge et al; licensee BioMed Central Ltd. 2011 Mudge et al; licensee BioMed Central Ltd. |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 5PM DOA |
DOI | 10.1186/1471-2369-12-20 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef PubMed Central (Full Participant titles) Directory of Open Access Journals |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1471-2369 |
EndPage | 20 |
ExternalDocumentID | oai_doaj_org_article_8565f4bf30e14ed0a85ea3b055b5dc4a oai_biomedcentral_com_1471_2369_12_20 A258004316 10_1186_1471_2369_12_20 21569446 |
Genre | Journal Article |
GeographicLocations | Australia |
GeographicLocations_xml | – name: Australia |
GroupedDBID | --- -A0 0R~ 23N 2VQ 2WC 3V. 4.4 53G 5GY 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AAWTL ABUWG ACGFO ACGFS ACIHN ACPRK ACRMQ ADBBV ADINQ ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHSBF AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C1A C24 C6C CCPQU CGR CS3 CUY CVF DIK DU5 E3Z EBLON EBS ECM EIF EJD EMB EMOBN F5P FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE IAO IHR INH INR IPNFZ ITC KQ8 M1P M48 M~E NPM O5R O5S OK1 P2P PGMZT PIMPY PQQKQ PROAC PSQYO RBZ RIG RNS ROL RPM RSV SMD SOJ SV3 TR2 UKHRP W2D WOQ WOW XSB AAYXX CITATION ABVAZ AFGXO AFNRJ 5PM |
ID | FETCH-LOGICAL-b584t-6a344aaa246d72d208c6cc851b99c3f255f7ec04dc0bb90e9e764ae7c23a56303 |
IEDL.DBID | RBZ |
ISSN | 1471-2369 |
IngestDate | Tue Oct 22 15:11:05 EDT 2024 Tue Sep 17 21:22:47 EDT 2024 Wed May 22 07:17:05 EDT 2024 Tue Nov 19 21:01:56 EST 2024 Tue Nov 12 23:22:41 EST 2024 Fri Dec 06 02:47:41 EST 2024 Sat Sep 28 07:48:01 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
License | 2011 Mudge et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-b584t-6a344aaa246d72d208c6cc851b99c3f255f7ec04dc0bb90e9e764ae7c23a56303 |
OpenAccessLink | http://dx.doi.org/10.1186/1471-2369-12-20 |
PMID | 21569446 |
PageCount | 1 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_8565f4bf30e14ed0a85ea3b055b5dc4a pubmedcentral_primary_oai_pubmedcentral_nih_gov_3107169 biomedcentral_primary_oai_biomedcentral_com_1471_2369_12_20 gale_infotracmisc_A258004316 gale_infotracacademiconefile_A258004316 crossref_primary_10_1186_1471_2369_12_20 pubmed_primary_21569446 |
PublicationCentury | 2000 |
PublicationDate | 2011-05-13 |
PublicationDateYYYYMMDD | 2011-05-13 |
PublicationDate_xml | – month: 05 year: 2011 text: 2011-05-13 day: 13 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | BMC nephrology |
PublicationTitleAlternate | BMC Nephrol |
PublicationYear | 2011 |
Publisher | BioMed Central Ltd BioMed Central BMC |
Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
References | 16722024 - Perit Dial Int. 2006 May-Jun;26(3):320-7 2913801 - Am J Med Sci. 1989 Jan;297(1):9-11 16595583 - Nephrol Dial Transplant. 2006 Aug;21(8):2217-24 18385391 - Clin J Am Soc Nephrol. 2008 Jul;3(4):1131-8 4722760 - Trans Am Soc Artif Intern Organs. 1973;19:446-9 2769017 - J Lab Clin Med. 1989 Sep;114(3):237-42 9430871 - Nephrol Dial Transplant. 1997 Dec;12(12):2679-82 18454706 - Nefrologia. 2008;28(2):168-73 15802033 - Ann Clin Biochem. 2005 Jan;42(Pt 1):51-4 7241891 - Kidney Int. 1981 Apr;19(4):587-92 5545116 - J Clin Invest. 1971 Mar;50(3):492-9 16112051 - Am J Kidney Dis. 2005 Aug;46(2):316-9 1605980 - J Paediatr Child Health. 1992 Jun;28(3):257-9 14520607 - Am J Kidney Dis. 2003 Oct;42(4 Suppl 3):S1-201 1244532 - N Engl J Med. 1976 Jan 22;294(4):184-8 17498116 - Nephrology (Carlton). 2007 Jun;12(3):224-33 15698446 - Kidney Int. 2005 Mar;67(3):1062-9 7243773 - Proc Eur Dial Transplant Assoc. 1980;17:226-33 6708989 - N Engl J Med. 1984 Apr 26;310(17):1079-84 84261 - Lancet. 1979 Feb 24;1(8113):406-9 7295112 - Arch Neurol. 1981 Oct;38(10):656-8 2689754 - Kidney Int. 1989 Dec;36(6):949-53 15284307 - J Am Soc Nephrol. 2004 Aug;15(8):2208-18 3626303 - Kidney Int. 1987 Jul;32(1):96-101 8846523 - Clin Nephrol. 1996 Feb;45(2):111-9 17728707 - Kidney Int. 2007 Nov;72(9):1130-7 1564520 - J Neurol Sci. 1992 Feb;107(2):210-8 15327423 - Kidney Int. 2004 Sep;66(3):1239-47 58273 - Lancet. 1976 Jun 5;1(7971):1235 10516350 - Am J Kidney Dis. 1999 Oct;34(4):688-93 3778707 - ASAIO Trans. 1986 Jul-Sep;32(1):171-6 MD Arenas (204_CR5) 2008; 28 AA Bakir (204_CR15) 1986; 32 S Mazzaferro (204_CR11) 1997; 12 H Graf (204_CR6) 1981; 19 L Woodard-Knight (204_CR13) 1992; 28 IS Parkinson (204_CR7) 1979; 1 AI Short (204_CR9) 1980; 17 GA Block (204_CR23) 2004; 15 E Slatopolsky (204_CR1) 1971; 50 B Manns (204_CR26) 2004; 66 GD Smith (204_CR10) 1987; 32 DH Froment (204_CR17) 1989; 114 B Lacour (204_CR31) 2005; 67 JM Candy (204_CR4) 1992; 107 JA Flendrig (204_CR8) 1976; 1 CM Foley (204_CR12) 1981; 38 JA Jaffe (204_CR19) 2005; 46 CL van Eps (204_CR22) 2007; 12 BB Kirschbaum (204_CR16) 1989; 297 WN Suki (204_CR27) 2007; 72 SC Cheng (204_CR25) 2008; 3 204_CR24 PM Gault (204_CR20) 2005; 42 SP Andreoli (204_CR14) 1984; 310 BA Molitoris (204_CR18) 1989; 36 MJ Janssen (204_CR28) 1996; 45 GB Spasovski (204_CR30) 2006; 21 AC Alfrey (204_CR3) 1976; 294 KP Katopodis (204_CR29) 2006; 26 E Rutherford (204_CR2) 1973; 19 AT Kausz (204_CR21) 1999; 34 |
References_xml | – volume: 19 start-page: 587 year: 1981 ident: 204_CR6 publication-title: Kidney Int doi: 10.1038/ki.1981.56 contributor: fullname: H Graf – volume: 12 start-page: 224 year: 2007 ident: 204_CR22 publication-title: Nephrology (Carlton) doi: 10.1111/j.1440-1797.2006.00712.x contributor: fullname: CL van Eps – volume: 3 start-page: 1131 year: 2008 ident: 204_CR25 publication-title: Clin J Am Soc Nephrol doi: 10.2215/CJN.04211007 contributor: fullname: SC Cheng – volume: 294 start-page: 184 year: 1976 ident: 204_CR3 publication-title: N Engl J Med doi: 10.1056/NEJM197601222940402 contributor: fullname: AC Alfrey – volume: 32 start-page: 96 year: 1987 ident: 204_CR10 publication-title: Kidney Int doi: 10.1038/ki.1987.177 contributor: fullname: GD Smith – volume: 297 start-page: 9 year: 1989 ident: 204_CR16 publication-title: Am J Med Sci doi: 10.1097/00000441-198901000-00003 contributor: fullname: BB Kirschbaum – volume: 1 start-page: 1235 year: 1976 ident: 204_CR8 publication-title: Lancet doi: 10.1016/S0140-6736(76)92177-2 contributor: fullname: JA Flendrig – volume: 38 start-page: 656 year: 1981 ident: 204_CR12 publication-title: Arch Neurol doi: 10.1001/archneur.1981.00510100084016 contributor: fullname: CM Foley – volume: 46 start-page: 316 year: 2005 ident: 204_CR19 publication-title: Am J Kidney Dis doi: 10.1053/j.ajkd.2005.04.020 contributor: fullname: JA Jaffe – volume: 12 start-page: 2679 year: 1997 ident: 204_CR11 publication-title: Nephrol Dial Transplant doi: 10.1093/ndt/12.12.2679 contributor: fullname: S Mazzaferro – volume: 310 start-page: 1079 year: 1984 ident: 204_CR14 publication-title: N Engl J Med doi: 10.1056/NEJM198404263101704 contributor: fullname: SP Andreoli – volume: 15 start-page: 2208 year: 2004 ident: 204_CR23 publication-title: J Am Soc Nephrol doi: 10.1097/01.ASN.0000133041.27682.A2 contributor: fullname: GA Block – volume: 17 start-page: 226 year: 1980 ident: 204_CR9 publication-title: Proc Eur Dial Transplant Assoc contributor: fullname: AI Short – volume: 1 start-page: 406 year: 1979 ident: 204_CR7 publication-title: Lancet doi: 10.1016/S0140-6736(79)90883-3 contributor: fullname: IS Parkinson – volume: 26 start-page: 320 year: 2006 ident: 204_CR29 publication-title: Perit Dial Int doi: 10.1177/089686080602600308 contributor: fullname: KP Katopodis – volume: 50 start-page: 492 year: 1971 ident: 204_CR1 publication-title: J Clin Invest doi: 10.1172/JCI106517 contributor: fullname: E Slatopolsky – volume: 72 start-page: 1130 year: 2007 ident: 204_CR27 publication-title: Kidney Int doi: 10.1038/sj.ki.5002466 contributor: fullname: WN Suki – volume: 21 start-page: 2217 year: 2006 ident: 204_CR30 publication-title: Nephrol Dial Transplant doi: 10.1093/ndt/gfl146 contributor: fullname: GB Spasovski – volume: 67 start-page: 1062 year: 2005 ident: 204_CR31 publication-title: Kidney Int doi: 10.1111/j.1523-1755.2005.00171.x contributor: fullname: B Lacour – volume: 28 start-page: 168 year: 2008 ident: 204_CR5 publication-title: Nefrologia contributor: fullname: MD Arenas – volume: 42 start-page: 51 year: 2005 ident: 204_CR20 publication-title: Ann Clin Biochem doi: 10.1258/0004563053026862 contributor: fullname: PM Gault – volume: 28 start-page: 257 year: 1992 ident: 204_CR13 publication-title: J Paediatr Child Health doi: 10.1111/j.1440-1754.1992.tb02658.x contributor: fullname: L Woodard-Knight – volume: 32 start-page: 171 year: 1986 ident: 204_CR15 publication-title: ASAIO Trans contributor: fullname: AA Bakir – volume: 45 start-page: 111 year: 1996 ident: 204_CR28 publication-title: Clin Nephrol contributor: fullname: MJ Janssen – volume: 19 start-page: 446 year: 1973 ident: 204_CR2 publication-title: Trans Am Soc Artif Intern Organs doi: 10.1097/00002480-197301900-00077 contributor: fullname: E Rutherford – ident: 204_CR24 doi: 10.1016/S0272-6386(03)00905-3 – volume: 66 start-page: 1239 year: 2004 ident: 204_CR26 publication-title: Kidney Int doi: 10.1111/j.1523-1755.2004.00877.x contributor: fullname: B Manns – volume: 107 start-page: 210 year: 1992 ident: 204_CR4 publication-title: J Neurol Sci doi: 10.1016/0022-510X(92)90291-R contributor: fullname: JM Candy – volume: 114 start-page: 237 year: 1989 ident: 204_CR17 publication-title: J Lab Clin Med contributor: fullname: DH Froment – volume: 36 start-page: 949 year: 1989 ident: 204_CR18 publication-title: Kidney Int doi: 10.1038/ki.1989.286 contributor: fullname: BA Molitoris – volume: 34 start-page: 688 year: 1999 ident: 204_CR21 publication-title: Am J Kidney Dis doi: 10.1016/S0272-6386(99)70394-X contributor: fullname: AT Kausz |
SSID | ssj0017840 |
Score | 2.1183443 |
Snippet | Aluminium-containing phosphate binders have long been used for treatment of hyperphosphatemia in dialysis patients. Their safety became controversial in the... Background Aluminium-containing phosphate binders have long been used for treatment of hyperphosphatemia in dialysis patients. Their safety became... BACKGROUND: Aluminium-containing phosphate binders have long been used for treatment of hyperphosphatemia in dialysis patients. Their safety became... Abstract Background Aluminium-containing phosphate binders have long been used for treatment of hyperphosphatemia in dialysis patients. Their safety became... |
SourceID | doaj pubmedcentral biomedcentral gale crossref pubmed |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | 20 |
SubjectTerms | Aluminum - adverse effects Aluminum - therapeutic use Aluminum compounds Bone Diseases - chemically induced Care and treatment Chelating Agents - adverse effects Chelating Agents - therapeutic use Chronic Disease Debate Health aspects Hemodialysis patients Humans Hyperphosphatemia - drug therapy Kidney Diseases - therapy Lanthanum - therapeutic use Phosphorus imbalance Polyamines - therapeutic use Renal Dialysis - adverse effects Sevelamer |
SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlh9JLafp0kxQdCu1FRNbLEjmE9BFCIT01kJuQZJk1tN4l3e3vz4ztNRE99NKrRjaSZqT5JM18IuS9kLG21tVMdq1h4K81C6q1zGSnVRIhcInZyNffzdWN-narbx889YUxYRM98DRwpxYQR6diJ3muVW55sDoHGbnWUbdJTdCIi_1mar4_aOyUCglLLxPSuJnUp7bmdCnDoAR85rtIdP9Z-KeRxn9ZrBcXVYZPPvBHl8_I0xlI0oupA4fkUR6ek8fX81X5CxK-rGmAlacf-t0vhs6qpZvV-vdmBeiSxn5MaqEYqd4Pu0y3a7oKfzINFOMNaT-Moj1vFR0yKH08gaf7vKrzl-Tm8uuPz1dsfk-BRYAZW2aCVCqEIJRpG9EKbpNJCSBXdC7JDjYXXZMTV23iMTqeXW6MCrlJQgakEZOvyMGwHvIbzPTmKQYLaClb1WpQuLMmuSZI04FXTBU5K0bVbybuDI9s1qUEJpZHnXjUia-FF7wiH_c6WD4cNyvW_F31E-qo-P9YADbkZxvy_7KhinxADXuc09CmFObUBOgrsmP5C6EtXpnWpiLHRU2Yi6kQv55MY2kPICrjYMtdkaYwmqLBpWToVyPNNwBvpDJ6-z96eESeTIfhmtXymBxs73b5BNDUNr4bJ849uNQc0g priority: 102 providerName: Directory of Open Access Journals – databaseName: PubMed (Medline) dbid: RPM link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELbaHhAXxJtAQT4gwcVdx6_Y4oBKoaqQFnGgUm-W7ThspG6yKrv8fsbeZIXFjWsmjiaZGc9ne-YLQm8Z97XWpia8axWBfC2JE60mKhopAnOO8tSNvPymrq7F1xt5c4Tk3AuTi_aD78-G2_XZ0K9ybeVmHRZzndji-_ICIEkieVkco2NIv_MSfTo6aGDJMnH41Fotaph9CeMqk_4zmsl_pTIiId6ixf22yEyZwP8wTR-SU1k4-VcmunyIHkwQEp_vVX2EjuLwGN1bTofkT5D7PGIHc04_9Ls1SWmqxZvV-GuzAlyJfZ_bWXCqUe-HXcTbEa_c74gdTpWGuB-yaGaswkMEc-e9dzx3VH18iq4vv_y4uCLTnxSIB4CxJcpxIZxzTKi2YS2jOqgQAGx5YwLvYFnRNTFQ0QbqvaHRxEYJF5vAuEsEYvwZOhnGIb5IPd40eKcBJ0UtWgmmNloF0ziuOsiHoUIfiq9qN3vWDJt4rEsJhJRN5rHJPLZmltEKvZ9tcBiYlyla_Xvrp2Sj4vn5wnj3007eYjXg1U74jtNYi9hSp2V03FMpvWyDcBV6lyxsUzSDTsFNTQnwrokXy54zqdNhaa0qdFrcCVEYCvHzvWsc9JndrEJN4TSFwqUE_D0TfE_-_fK_R75C9_d735LU_BSdbO928TWAp61_k4PlD6U5Gq4 priority: 500 providerName: National Library of Medicine – databaseName: Scholars Portal Open Access Journals dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV1LixQxEA6ygngR37aukoOgl2g6r04QWdbHsgjjyYG9hSSddhp2u8fZGdF_byXTM2twvXYepFNVqa-S1BeEXjLua61NTXjXKgL-WhInWk1UNFIE5hzlKRt59lWdzsWXM3l29RzQNIGX14Z26T2p-er8za8fv4_A4N9ng9fqbQ0LLGFcZV5_BvH7TQZuMd3vmomrI4UGQpmJ2-eaRpkUWCojEhIuUt_PC4-Vif33y_feaZUXKv_yUCd30Z0JWuLjrS7cQzficB_dmk2H5w-Q-zRiB2tRP_SbC5LcV4uXi_FyuQC8iX2f01xwurveD5uI1yNeuJ8RO5xuIOJ-yEU7Jis8RFCDvCePd5lWRw_R_OTzt4-nZHphgXgAHmuiHBfCOceEahvWMqqDCgFAmDcm8A7Cja6JgYo2UO8NjSY2SrjYBMZdIhbjj9DBMA7xScr9psE7DfgpatFKUAGjVTCN46oDPxkq9K6YVbvcsmnYxG9dloCp2SQem8Rja2YZrdDrnQz2DXP4otW_VT8kGRX95w_j6rudzNFqwLGd8B2nsRaxpU7L6LinUnrZBuEq9CpJ2Ca9gzEFNyUrwL8mvix7zKROh6i1qtBhUROsMxTFj7eqsR_PTs0q1BRKUwy4LBn6RSb-BiieyI2e_rfPZ-j2ds9bkpofooP1ahOfA2ha-xfZGP4A2RkT6Q priority: 102 providerName: Scholars Portal |
Title | Do aluminium-based phosphate binders continue to have a role in contemporary nephrology practice? |
URI | https://www.ncbi.nlm.nih.gov/pubmed/21569446 http://dx.doi.org/10.1186/1471-2369-12-20 https://pubmed.ncbi.nlm.nih.gov/PMC3107169 https://doaj.org/article/8565f4bf30e14ed0a85ea3b055b5dc4a |
Volume | 12 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZQKyEuqJRXSln5gAQXC8evOOKAtpSqWmk5AJUqLpbtONpIkF21u_x-xk424MKNSw6xEzkej-ebGc8XhF4x7kqt65LwtlEE7LUkVjSaqFBL4Zm1lMdq5OUndXklFtfy-jdZ9J0MfqnV2xK2T8K4Sqz9DLzzQ_AYePSzPp99mxIGlR5qH_edRxaff7zgTmX798wgJd7-aXeebFJ-XvIPA3RxhB6OyBHPB1E_QvdCf4zuL8fc-GNkz9fYwlbT9d3uB4nWqcGb1fp2swI4iV2XqlhwPJre9buAt2u8sj8DtjgeMMRdn5r2RFW4DyDlFHLH-0Kq90_Q1cXHrx8uyfgDBeIAV2yJslwIay0TqqlYw6j2ynvAWK6uPW_Bm2ir4KloPHWupqEOlRI2VJ5xG3nD-FN00K_78DyWdlPvrAZ4FLRoJEi41srXleWqBTPoC_Qum1WzGcgyTKSvzltAk0yUiYkyMSUzjBbozV4G04PJO9Hq765nUUbZ-9MNWDNm1DajAaa2wrWchlKEhlotg-WOSulk44Ut0OsoYROVGMbk7ViLAN8a6bDMnEkdc6SlKtBp1hOUz2fNz4alMY0HIJSqwccuUJUtmmzAeUvfrRKvNyDtyF108l9T-QI9GMLekpT8FB1sb3bhJeCmrZuhw_l88WUxS3EHuC6FniUtmqUg1y81Ahi9 |
link.rule.ids | 108,230,314,727,780,784,864,885,2102,2221,24318,24937,27924,27925,53791,53793,75811,75812 |
linkProvider | BioMedCentral |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3LbtQwFLWqIgEbxJtAAS-QYGNI_IojFqgFqgE6XaBWqthYtuMwkdpkVGb4fq6dBzWwY5vrWLav7Xv8OMcIvaDMFkpVBWFNLQnEa0EMrxWRvhLcUWNyFtjIy2O5OOWfz8TZDlpMXBh74ToP1Yh7yq-vUtDP47w9XRcbRruSbwqYXQllMor6U1i8XwMEXIS3DL4efJvPE0o1UCOnxKPIzz8y-IP4fp7EqyjrP0_ec8hKr1NeiU-Ht9GtEVji_aHkd9CO7-6i68vx6PweMh96bGAmart2e0FC8KrxetX_WK8AbWLbRpILDjfX227r8abHK_PTY4PD_UPcdtE06Vjh362HJ57Vu_vo9PDjyfsFGd9XIBZgx4ZIwzg3xlAu65LWNFdOOgcQzFaVYw0sNprSu5zXLre2yn3lS8mNLx1lJsiKsQdot-s7_ygwv3NnjQL05BWvBXSASklXlYbJBqKky9DbpFX1etDS0EHdOrWAl3XwiQ4-0QXVNM_Qq8kH849x8aLk30kPgo-S_OOH_vK7HjuPVoBiG24blvuC-zo3SnjDbC6EFbXjJkMvg4d1GONQJmdGqgLUNahl6X0qVDhCLWSG9pKUMDZdYn44dI25PICwZAVL8AyVSadJCpxaunYVZb8BiAdpo8f_1ZTP0Y3FyfJIH306_vIE3Rx2yAUp2B7a3Vxu_VOAWBv7LI6eX2jjJAM |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZQkSouiDeBAj4gwcU08SuOOKCWsiqPVghRqeJi-ZVuRJusyi6_n7GTXWrgxi2KHcvxzHg-x_6-IPScMlsp1VSEtV4SyNeCGO4VkaER3FFjShbZyEfH8vCEfzgVp5OkUOTC2AvXB3iN9E351VUK-nmat-HCfd9d-HYMdyV3K5heCWUyqfpTWL1fBwicYvTL_rfNhkKtRm7kuvKk8vOPBv5gvp9nCSvp-m9m703Oys9TXklQs1vo5oQs8d7oCrfRtdDfQdtH0975XWQOBmxgKur6bnVBYvbyeDEffizmADex7RLLBcej612_Cng54Ln5GbDB8QAi7vpUtBaywr-HD6-JVm_uoZPZu69vD8n0gwViAXcsiTSMc2MM5dLX1NNSOekcYDDbNI61sNpo6-BK7l1pbVOGJtSSm1A7ykzUFWP30VY_9OFhpH6XzhoF8Cko7gV4QKOka2rDZAtp0hXodTaqejGKaegob52XgJl1tImONtEV1bQs0Mu1DTYPptWLkn9X3Y82ytpPN4bLMz1Fo1YAY1tuW1aGigdfGiWCYbYUwgrvuCnQi2hhHYM8epyZuArwrlEuS-9RoeIeaiULtJPVhOB0WfGD0TU2_QGIJRtYgxeozpwm63Be0nfzpPsNSDxqGz36r6F8hrY_H8z0p_fHHx-jG-MXckEqtoO2lper8AQg1tI-TcHzC-KTI84 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Do+aluminium-based+phosphate+binders+continue+to+have+a+role+in+contemporary+nephrology+practice%3F&rft.jtitle=BMC+nephrology&rft.au=Mudge%2C+David+W&rft.au=Johnson%2C+David+W&rft.au=Hawley%2C+Carmel+M&rft.au=Campbell%2C+Scott+B&rft.date=2011-05-13&rft.eissn=1471-2369&rft.volume=12&rft.spage=20&rft_id=info:doi/10.1186%2F1471-2369-12-20&rft_id=info%3Apmid%2F21569446&rft.externalDocID=21569446 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2369&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2369&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2369&client=summon |